intertrochanteric fx of femur. Pertrochanteric fracture
Conditions
Interventions
Intervention 1: Intervention group: Each patient receives two 500 mg tablets of tranexamic acid (a total of 1 g) two hours before surgery, administered by a nurse unaware of the study. Intervention 2:
Sponsors
Karaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age 60 to 80 years ASA class I or II Confirmed intertrochanteric fracture (stable or unstable) Indication for dynamic hip screw (DHS) surgery No history of active cardiovascular disease or recent thromboembolism No history of severe renal or hepatic failure No history of hypersensitivity to tranexamic acid Normal coagulation profile and no use of anticoagulant medications that have not been discontinued before surgery
Exclusion criteria
Exclusion criteria: Hypersensitivity to tranexamic acid Any medical condition preventing spinal anesthesia or surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of bleeding. Timepoint: Intraoperative, 24, and 72 hours postoperatively. Method of measurement: Suctioned blood volume; Number of gauze used; Drainage blood volume; Preoperative hemoglobin, 24 and 72 hours postoperatively. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of deep vein thrombosis(DVT) and pulmonary embolism(PE). Timepoint: During the patient's hospitalization after surgery. Method of measurement: The occurrence of deep vein thrombosis (DVT) will be assessed using Doppler ultrasound before discharge, and pulmonary embolism (PE) symptoms will be evaluated, if necessary, using imaging techniques such as CT scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzam Mohebbi
Karaj University of Medical Sciences
Outcome results
None listed